MedTrace Logo

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

NCT03879382 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-06

No results posted yet for this study

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.

Conditions

  • POMES Syndrome
  • Relapsed and Refractory POMES Syndrome

Interventions

BIOLOGICAL

anti-CD19/BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Hrain Biotechnology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-27
Primary Completion
2020-08-30
Completion
2022-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03879382 on ClinicalTrials.gov